Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention
| dc.contributor.author | Ioannidis, J. P. | en |
| dc.contributor.author | Karvouni, E. | en |
| dc.contributor.author | Katritsis, D. G. | en |
| dc.date.accessioned | 2015-11-24T19:03:36Z | |
| dc.date.available | 2015-11-24T19:03:36Z | |
| dc.identifier.issn | 0735-1097 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19916 | |
| dc.rights | Default Licence | - |
| dc.subject | Angioplasty, Balloon, Coronary | en |
| dc.subject | Atherectomy | en |
| dc.subject | Coronary Disease/*mortality/*therapy | en |
| dc.subject | Creatine Kinase/*blood | en |
| dc.subject | Creatine Kinase, MB Form | en |
| dc.subject | Follow-Up Studies | en |
| dc.subject | Humans | en |
| dc.subject | Isoenzymes/*blood | en |
| dc.subject | Risk Assessment | en |
| dc.subject | Stents | en |
| dc.subject | Time Factors | en |
| dc.title | Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention | en |
| heal.abstract | OBJECTIVES: The aim of this study was to assess whether small creatine kinase-MB isoenzyme (CK-MB) elevations after percutaneous coronary intervention (PCI) affect the subsequent mortality risk. BACKGROUND: Several studies have evaluated the relationship of CK-MB levels after PCI with the subsequent risk of death. While there is consensus that elevations exceeding 5 times the upper limit of normal increase mortality significantly, there is uncertainty about the exact clinical impact of smaller CK-MB elevations. METHODS: We performed a meta-analysis of seven studies with CK-MB measurements and survival outcomes on 23230 subjects who underwent PCI. Data were combined with random effects models. RESULTS: Mean follow-up was 6 to 34 months per study. By random effects, 19% (95% confidence interval [CI], 16% to 23%) had one- to five-fold CK-MB elevations, while only 6% (95% CI, 5% to 9%) had >5-fold elevations. Compared with subjects with normal CK-MB, there was a dose-response relationship with relative risks for death being 1.5 (95% CI, 1.2 to 1.8, no between-study heterogeneity) with one- to three-fold CK-MB elevations, 1.8 (95% CI, 1.4 to 2.4, no between-study heterogeneity) with three- to five-fold CK-MB elevations, and 3.1 (95% CI, 2.3 to 4.2, borderline between-study heterogeneity) with over five-fold CK-MB elevations (p < 0.001 for all). CONCLUSIONS: Any increase in CK-MB after PCI is associated with a small, but statistically and clinically significant, increase in the subsequent risk of death. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/14563583 | - |
| heal.journalName | J Am Coll Cardiol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2003 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: